General Announcement::Company Statement

Issuer & Securities

Issuer/ Manager
BIOCON BIOLOGICS GLOBAL PLC
Securities
BIOCONBIO US$800M6.67%N291009A - US090978AA56 - RJUB
BIOCONBIO US$800M6.67%N291009R - USG11185AA61 - KSEB
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
26-Apr-2025 18:48:13
Status
New
Announcement Sub Title
Company Statement
Announcement Reference
SG250426OTHRYK3Q
Submitted By (Co./ Ind. Name)
Biocon Biologics Limited / Akhilesh Nand
Designation
Company Secretary
Effective Date and Time of the event
28/04/2025 00:01:00
Description (Please provide a detailed description of the event in the box below)
Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe

Attachments

BBL_SGX_Denosumab_CHMP_26042025.pdf
Total size =360K